These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10349474)

  • 1. [Prognostic, therapeutic, exploratory tool for carcinogenesis: what is the role of ERBB-2 in breast cancer?].
    Penault-Llorca F; Jacquemier J
    Ann Pathol; 1999 Apr; 19(2):103-15. PubMed ID: 10349474
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunohistochemical assessment of tumour behaviour and patient prognosis in human breast cancer.
    Barnes DM
    Dis Markers; 1991; 9(3-4):159-65. PubMed ID: 1687522
    [No Abstract]   [Full Text] [Related]  

  • 3. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
    Malamou-Mitsi VD; Syrrou M; Georgiou I; Pagoulatos G; Agnantis NJ
    J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnosis and management of pre-invasive breast disease: another point of view.
    Badve S
    Breast Cancer Res; 2004; 6(1):E3; discussion E4. PubMed ID: 14680489
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prognostic-predictive factors and therapeutic choices in invasive carcinoma of the breast].
    Puglisi F; Di Loreto C; Beltrami CA
    Ann Ital Chir; 1999; 70(3):335-41. PubMed ID: 10466235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu (c-erb-B2) gene and protein in breast cancer.
    Ross JS; Fletcher JA
    Am J Clin Pathol; 1999 Jul; 112(1 Suppl 1):S53-67. PubMed ID: 10396301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptome profiling in clinical breast cancer: from 3D culture models to prognostic signatures.
    Fournier MV; Martin KJ
    J Cell Physiol; 2006 Dec; 209(3):625-30. PubMed ID: 17001673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
    Erdogan S; Ergin M; Tuncer I
    Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality assurance of predictive markers in breast cancer.
    Rhodes A; Barnes DM
    Methods Mol Med; 2004; 97():29-57. PubMed ID: 15064483
    [No Abstract]   [Full Text] [Related]  

  • 11. A health plan's integration of molecular diagnostics and the impact on treatment pathways for quality care.
    Wong W
    Manag Care; 2008 Jul; 17(7 Suppl 7):13-6; discussion 17-8. PubMed ID: 19093337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
    Huber KE; Carey LA; Wazer DE
    Semin Radiat Oncol; 2009 Oct; 19(4):204-10. PubMed ID: 19732684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New generation of molecular prognostic and predictive tests for breast cancer.
    Pusztai L; Cristofanilli M; Paik S
    Semin Oncol; 2007 Apr; 34(2 Suppl 3):S10-6. PubMed ID: 17512431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
    Kaklamani V
    Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for breast cancer and their use in the clinical setting.
    Kapoor A; Vogel VG
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):269-81. PubMed ID: 15877524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004].
    Cutuli B; Fourquet A; Luporsi E; Arnould L; Caron Y; Cremoux Pd; Dilhuydy JM; Fondrinier E; Fourme E; Giard-Lefevre S; Blanc-Onfroy ML; Lemanski C; Mauriac L; Sigal-Zafrani B; Tardivon A; This P; Tunon de Lara C; Kirova Y; Fabre N;
    Bull Cancer; 2005 Feb; 92(2):155-68. PubMed ID: 15749645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of HER-2/neu oncogene amplification in determination of outcome of patients with cancer.
    Sethi S
    Am J Clin Pathol; 2000 Jun; 113(6):905-6. PubMed ID: 10874893
    [No Abstract]   [Full Text] [Related]  

  • 19. Current status of prognostic profiling in breast cancer.
    Pusztai L
    Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.